Autosomal dominant ADAR c.3019G>A (p.(G1007R)) variant is an important mimic of hereditary spastic paraplegia and cerebral palsy
暂无分享,去创建一个
Y. Crow | K. Kothur | Kirsty Stewart | G. Ho | S. Mohammad | C. Troedson | Jennifer Lewis | S. Paget | V. X. Han | Marion Stoll | Russell C. Dale | H. Jones | Dugald O'Neill
[1] Y. Crow,et al. Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi–Goutières syndrome , 2021, Developmental medicine and child neurology.
[2] Martin A. M. Reijns,et al. cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing , 2020, Nature Genetics.
[3] A. Vanderver,et al. Janus Kinase Inhibition in the Aicardi-Goutières Syndrome. , 2020, The New England journal of medicine.
[4] E. Bertini,et al. Movement disorders in ADAR1 disease: Insights from a comprehensive cohort. , 2020, Parkinsonism & related disorders.
[5] I. Heyman,et al. Psychiatric comorbidity is common in dystonia and other movement disorders , 2020, Archives of Disease in Childhood.
[6] Y. Crow,et al. Magnetic resonance imaging pattern recognition in childhood bilateral basal ganglia disorders , 2020, Brain communications.
[7] R. Taipa,et al. Diagnosis of Aicardi‐Goutières Syndrome in Adults: A Case Series , 2020, Movement disorders clinical practice.
[8] A. Vanderver,et al. Genetic and phenotypic spectrum associated with IFIH1 gain-of-function , 2020, Human mutation.
[9] Y. Crow,et al. Treatments in Aicardi–Goutières syndrome , 2020, Developmental medicine and child neurology.
[10] R. Badolato,et al. Novel and emerging treatments for Aicardi-Goutières syndrome , 2019, Expert review of clinical immunology.
[11] Y. Crow,et al. An open-label trial of JAK 1/2 blockade in progressive IFIH1-associated neuroinflammation , 2018, Neurology.
[12] A. Vanderver,et al. Genetic, Phenotypic, and Interferon Biomarker Status in ADAR1-Related Neurological Disease. , 2017, Neuropediatrics.
[13] Y. Crow,et al. Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview , 2016, The Journal of experimental medicine.
[14] M. Pranzatelli,et al. Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome , 2016, Brain and Development.
[15] M. Akiyama,et al. Dyschromatosis Symmetrica Hereditaria and Aicardi-Goutières Syndrome 6 Are Phenotypic Variants Caused by ADAR1 Mutations. , 2016, The Journal of investigative dermatology.
[16] Y. Crow,et al. Aicardi–Goutières syndrome and the type I interferonopathies , 2015, Nature Reviews Immunology.
[17] L. Lagae,et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1 , 2015, American journal of medical genetics. Part A.
[18] Abhijit Dutta,et al. Dyschromatosis symmetrica hereditaria with neurological abnormalities. , 2014, Indian journal of dermatology, venereology and leprology.
[19] A. Munnich,et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1 , 2013, Journal of Medical Genetics.
[20] T. Awaya,et al. Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus. , 2013, Rheumatology.
[21] John H Livingston,et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature , 2012, Nature Genetics.
[22] R. Dale,et al. Biomarkers of inflammatory and auto-immune central nervous system disorders , 2010, Current opinion in pediatrics.
[23] F. Kaliyadan,et al. Acral dyschromatosis with developmental regression and dystonia in a seven-year-old child: dyschromatosis symmetrica hereditaria variant or a new syndrome? , 2009, Indian journal of dermatology, venereology and leprology.
[24] T. Negoro,et al. Dyschromatosis symmetrica hereditaria associated with neurological disorders , 2008, The Journal of dermatology.
[25] M. Komine,et al. Six novel mutations of the ADAR1 gene in patients with dyschromatosis symmetrica hereditaria: Histological observation and comparison of genotypes and clinical phenotypes , 2008, The Journal of dermatology.
[26] T. Hashimoto,et al. Dystonia, mental deterioration, and dyschromatosis symmetrica hereditaria in a family with ADAR1 mutation , 2006, Movement disorders : official journal of the Movement Disorder Society.
[27] H. Shimizu,et al. Mutation analysis of the ADAR1 gene in dyschromatosis symmetrica hereditaria and genetic differentiation from both dyschromatosis universalis hereditaria and acropigmentatio reticularis. , 2005, The Journal of investigative dermatology.
[28] Y. Sekijima,et al. [A case of idiopathic brain calcification associated with dyschromatosis symmetrica hereditaria, aplasia of dental root, and aortic valve sclerosis]. , 2001, Rinsho shinkeigaku = Clinical neurology.
[29] A. Pini,et al. Dyschromatosis symmetrica hereditaria associated with idiopathic torsion dystonia. A case report. , 1994, Acta dermato-venereologica.